Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Xilio Therapeutics is advancing its pipeline of masked immuno-oncology therapies, including XTX501, a bispecific PD-1 / masked IL-2, with plans for IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 [1][7] - The company is also developing a first-in-class multi-specific masked T cell engager targeting PSMA and STEAP1, with a development candidate expected to be nominated in Q2 2026 [3][11] - Xilio has extended its cash runway through the end of 2027, with cash and cash equivalents reported at $137.5 million as of December 31, 2025 [13][12] Pipeline Progress and Business Updates - XTX501 is designed to selectively stimulate PD-1 positive, antigen-experienced T cells, demonstrating robust monotherapy activity in preclinical studies [4] - The company is leveraging its proprietary masking technology to advance multiple masked T cell engager programs, including a collaboration with AbbVie [5][11] - Xilio plans to present new preclinical data for its CLDN18.2 program at the AACR Annual Meeting in April 2026 [11] Financial Performance - Collaboration and license revenue increased significantly to $13.7 million for Q4 2025, compared to $1.7 million in Q4 2024, and $43.8 million for the full year 2025, up from $6.3 million in 2024 [12][17] - Research and development expenses rose to $18.1 million for Q4 2025, compared to $8.8 million in Q4 2024, driven by IND-enabling studies and clinical development activities [12][17] - The net income for Q4 2025 was $10.4 million, a significant improvement from a net loss of $13.1 million in Q4 2024, while the net loss for the full year decreased to $35.0 million from $58.2 million [17][12]